Trial · NCT02300727
Study to See How Safe Curcumin is and How Well it Works When Used to Treat Mucositis in Patients Getting Chemotherapy
NCT02300727, Phase 1, Phase 2, Terminated, Amy Beres; results first posted 2019-05-31
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study to See How Safe Curcumin is and How Well it Works When Used to Treat Mucositis in Patients Getting Chemotherapy. Trials, record NCT02300727. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02300727
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study to See How Safe Curcumin is and How Well it Works When Used to Treat Mucositis in Patients Getting Chemotherapy
- NCT number
- NCT02300727
- Status
- Terminated
- Phases
- Phase 1, Phase 2
- Enrollment
- 6 participants, actual
- Lead sponsor
- Amy Beres
- Conditions
- Mucositis
- Interventions
- Curcumin-MTD, Mouthwash-standard pharmacy preparation, Curcumin
- First posted
- 2014-11-25
- Last updated
- 2019-05-31
- Results first posted
- 2019-05-31
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Serious and Non-Serious Adverse Events | reviewed weekly for 4 to 6 weeks | Number of Participants with Serious and Non-Serious Adverse Events. |
| Secondary | Change in Toxicities Graded by Health Care Providers Using the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | Baseline, weekly for 5 to 7 weeks | NA - Protocol ended early after failing to enroll sufficiently. Only 6 subjects enrolled, 5 completed, 1 withdrew. Zero participants analyzed. |
| Secondary | Change in Subjective Patient Self-assessment of Pain. | Baseline, weekly for 5 to 7 weeks | NA - Protocol ended early after failing to enroll sufficiently. Only 6 subjects enrolled, 5 completed, 1 withdrew. Insufficient data to analyze |
| Secondary | Change in Subjective Patient Self- Assessment of Oral Mucositis Measured by the Common Terminology Criteria for Adverse Events (CTCAE) and World Health Organization's (WHO's) Oral Toxicity Scale (OTS) | Baseline, weekly for 5 to 7 weeks | NA - Protocol ended early after failing to enroll sufficiently. Only 6 subjects enrolled, 5 completed, 1 withdrew. Insufficient data to analyze |
| Secondary | Change in Health Providers Assessment of Oral Mucositis and Healing Time Measured by the Common Terminology Criteria for Adverse Events (CTCAE) and World Health Organization's (WHO's) Oral Toxicity Scale (OTS) | Baseline, then weekly for 4 to 6 weeks | NA - Protocol ended early after failing to enroll sufficiently. Only 6 subjects enrolled, 5 completed, 1 withdrew. Insufficient data to analyze |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Serious and Non-Serious Adverse Events | reviewed weekly for 4 to 6 weeks | Protocol ended early after failing to enroll sufficiently. Only 6 subjects enrolled, 5 completed, 1 withdrew. Insufficient data to analyze. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Change in Toxicities Graded by Health Care Providers Using the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | Baseline, weekly for 5 to 7 weeks | |||
| SECONDARY | Change in Subjective Patient Self-assessment of Pain. | Baseline, weekly for 5 to 7 weeks | |||
| SECONDARY | Change in Subjective Patient Self- Assessment of Oral Mucositis Measured by the Common Terminology Criteria for Adverse Events (CTCAE) and World Health Organization's (WHO's) Oral Toxicity Scale (OTS) | Baseline, weekly for 5 to 7 weeks | |||
| SECONDARY | Change in Health Providers Assessment of Oral Mucositis and Healing Time Measured by the Common Terminology Criteria for Adverse Events (CTCAE) and World Health Organization's (WHO's) Oral Toxicity Scale (OTS) | Baseline, then weekly for 4 to 6 weeks |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Serious and Non-Serious Adverse Events | Mouthwash-standard Pharmacy Preparation | 0 | Participants | ||
| Number of Participants With Serious and Non-Serious Adverse Events | Curcumin | 0 | Participants | ||
| Number of Participants With Serious and Non-Serious Adverse Events | Curcumin-MTD 0.33g Dose | 0 | Participants | ||
| Number of Participants With Serious and Non-Serious Adverse Events | Curcumin-MTD 1g Dose | 0 | Participants | ||
| Number of Participants With Serious and Non-Serious Adverse Events | Curcumin- MTD 2g Dose | 0 | Participants | ||
| Number of Participants With Serious and Non-Serious Adverse Events | Curcumin- MTD 3g Dose | 0 | Participants |
Source ClinicalTrials.gov
Participant flow18
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Mouthwash-standard Pharmacy Preparation | 0 | |
| Overall Study | STARTED | Curcumin | 0 | |
| Overall Study | STARTED | Curcumin-MTD 0.33g Dose | 3 | |
| Overall Study | STARTED | Curcumin-MTD 1g Dose | 3 | |
| Overall Study | STARTED | Curcumin- MTD 2g Dose | 0 | |
| Overall Study | STARTED | Curcumin- MTD 3g Dose | 0 | |
| Overall Study | COMPLETED | Mouthwash-standard Pharmacy Preparation | 0 | |
| Overall Study | COMPLETED | Curcumin | 0 | |
| Overall Study | COMPLETED | Curcumin-MTD 0.33g Dose | 3 | |
| Overall Study | COMPLETED | Curcumin-MTD 1g Dose | 2 |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals18
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Mouthwash-standard Pharmacy Preparation | 0 | 0 |
| Total, all-cause mortality | Curcumin | 0 | 0 |
| Total, all-cause mortality | Curcumin-MTD 0.33g Dose | 0 | 3 |
| Total, all-cause mortality | Curcumin-MTD 1g Dose | 0 | 3 |
| Total, all-cause mortality | Curcumin-MTD 2g Dose | 0 | 0 |
| Total, all-cause mortality | Curcumin-MTD 3g Dose | 0 | 0 |
| Total, other adverse events | Mouthwash-standard Pharmacy Preparation | 0 | 0 |
| Total, other adverse events | Curcumin | 0 | 0 |
| Total, other adverse events | Curcumin-MTD 0.33g Dose | 0 | 3 |
| Total, other adverse events | Curcumin-MTD 1g Dose | 0 | 3 |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 adverse event totalsPapers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02300727
GET https://conductscience.org/api/trials/v1/NCT02300727/registered